Home / Health / HG Drug Access: A Postcode Lottery?
HG Drug Access: A Postcode Lottery?
29 Jun
Summary
- Severe HG sickness causes extreme vomiting and head-banging relief.
- Xonvea is an effective HG drug but not always first prescribed.
- Access to Xonvea varies by region, leading to inequitable care.
Hyperemesis Gravidarum (HG), a severe form of pregnancy sickness, can leave women unable to function due to extreme nausea and vomiting. For some, like Jasmeen Basi, the condition was so severe that it impacted her daily life, leading her to seek private medical care for effective treatment. She found Xonvea to be life-changing after struggling with other prescribed medications.
While Xonvea is recognized as a specifically labeled and effective treatment for HG by the MHRA, its prescription in the UK is influenced by local Integrated Care Boards (ICBs). This has resulted in an inequitable 'postcode lottery' for access, with some areas having stricter criteria than others, despite national guidance positioning it as an equal first-line option.
Experts, including Marianne Eldridge from Pregnancy Sickness Support, highlight that the majority of women find Xonvea highly effective. Professor Catherine Nelson-Piercy notes that while Xonvea is safe and effective, its higher cost compared to older antihistamines means it's not always the first choice for GPs. The Department of Health and Social Care acknowledges these disparities and is working towards a Single National Formulary to ensure more equitable access to medicines across the country.
